Horsham, United Kingdom

Ahmed Hamadi

USPTO Granted Patents = 1 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ahmed Hamadi: Innovator in Ghrelin Receptor Agonists

Introduction

Ahmed Hamadi is a notable inventor based in Horsham, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that interact with the ghrelin receptor. His work is essential in advancing treatments for various disorders mediated by this receptor.

Latest Patents

Ahmed Hamadi holds a patent for "3-spirocyclic piperidine derivatives as ghrelin receptor agonists." This invention relates to derivatives of formula (I), wherein the substituents are as defined in the specification. The patent also covers processes for the preparation of such derivatives, pharmaceutical compositions comprising these derivatives, and their use as a medicament for treating disorders or diseases mediated by the ghrelin receptor. He has 1 patent to his name.

Career Highlights

Ahmed is currently employed at Novartis AG, a leading global healthcare company. His role involves research and development in the pharmaceutical sector, where he focuses on innovative solutions for health challenges.

Collaborations

Throughout his career, Ahmed has collaborated with talented professionals, including Ameet Vijay Ambarkhane and Gurdip Bhalay. These collaborations have contributed to the advancement of his research and the successful development of his inventions.

Conclusion

Ahmed Hamadi is a distinguished inventor whose work on ghrelin receptor agonists has the potential to impact the treatment of various medical conditions. His contributions to the pharmaceutical industry exemplify the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…